A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression

Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin

(2013) Preeti Shah et al.   BREAST CANCER RESEARCH AND TREATMENT

FOXO3a Is a Major Target of Inactivation by PI3K/AKT Signaling in Aggressive Neuroblastoma

(2013) E. E. Santo et al.   CANCER RESEARCH

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor

(2013) Denise A. Yardley et al.   JOURNAL OF CLINICAL ONCOLOGY

HDAC Inhibitor Entinostat Restores Responsiveness of Letrozole-Resistant MCF-7Ca Xenografts to Aromatase Inhibitors through Modulation of Her-2

(2013) G. J. Sabnis et al.   MOLECULAR CANCER THERAPEUTICS

Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers

(2013) D Wetterskog et al.   ONCOGENE

HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade

(2013) Y J Kim et al.   ONCOGENE

PUMA and BIM Are Required for Oncogene Inactivation-Induced Apoptosis

(2013) G. R. Bean et al.   Science Signaling

Functional cooperation of miR-125a, miR-125b and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells

(2013) S Wang et al.   Cell Death & Disease

Mitochondria and FOXO3: breath or die

(2013) Judith Hagenbuchner et al.   Frontiers in Physiology

Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells

(2012) Samiha Mateen et al.   Epigenetics

Smoking Induces Epithelial-to-Mesenchymal Transition in Non-Small Cell Lung Cancer through HDAC-Mediated Downregulation of E-Cadherin

(2012) N. S. Nagathihalli et al.   MOLECULAR CANCER THERAPEUTICS

Improving Treatment of HER2-Positive Cancers: Opportunities and Challenges

(2012) H. M. Stern   Science Translational Medicine

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

(2011) Leiping Wang et al.   BMC CANCER

AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity

(2011) Sarat Chandarlapaty et al.   CANCER CELL

HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance

(2011) Xiaoping Huang et al.   CANCER LETTERS

Functional Activation of the Estrogen Receptor-  and Aromatase by the HDAC Inhibitor Entinostat Sensitizes ER-Negative Tumors to Letrozole

(2011) G. J. Sabnis et al.   CANCER RESEARCH

AKT/FOXO Signaling Enforces Reversible Differentiation Blockade in Myeloid Leukemias

(2011) Stephen M. Sykes et al.   CELL

Therapeutic prospects for epigenetic modulation

(2011) Tom D Heightman   EXPERT OPINION ON THERAPEUTIC TARGETS

FOXO3 Is Inhibited by Oncogenic PI3K/Akt Signaling but Can Be Reactivated by the NSAID Sulindac Sulfide

(2011) Carl Weidinger et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

(2011) J. T. Garrett et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MS-275 Sensitizes TRAIL-Resistant Breast Cancer Cells, Inhibits Angiogenesis and Metastasis, and Reverses Epithelial-Mesenchymal Transition In vivo

(2010) R. K. Srivastava et al.   MOLECULAR CANCER THERAPEUTICS

Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines

(2009) Y. Kataoka et al.   ANNALS OF ONCOLOGY

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

(2009) L. Liu et al.   CANCER RESEARCH

Histone deacetylase inhibitors: Potential in cancer therapy

(2009) P.A. Marks et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235

(2008) P. J.A. Eichhorn et al.   CANCER RESEARCH

The Forkhead Transcription Factor FOXO3a Increases Phosphoinositide-3 Kinase/Akt Activity in Drug-Resistant Leukemic Cells through Induction of PIK3CA Expression

(2008) R. C.-Y. Hui et al.   MOLECULAR AND CELLULAR BIOLOGY

EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach

(2007) Fotios Loupakis et al.   PHARMACOGENOMICS